AI assistant
Neumora Therapeutics, Inc. — Director's Dealing 2023
Sep 18, 2023
33366_dirs_2023-09-18_f2ec945f-8f57-4806-b72e-eb41e7ed8526.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Neumora Therapeutics, Inc. (NMRA)
CIK: 0001885522
Period of Report: 2023-09-14
Reporting Person: Lenz Robert A. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-09-14 | Common Stock | A | 352941 | — | Acquired | 352941 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-09-14 | Stock Option (Right to Buy) | $17 | A | 502934 | Acquired | 2033-09-13 | Common Stock (502934) | Direct |
Footnotes
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on September 11 of each year, with the first 1/4th vesting on September 11, 2024.
F2: 25% of the shares subject to the option vest on the first anniversary measured from September 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.